Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study
Grazia Arpino(University of Naples Federico II), Sabino De Placido, Claudio Zamagni(Policlinico S.Orsola-Malpighi), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Filippo Montemurro(Roche (Switzerland)), Lucio Laudadio(Ospedale "Floraspe Renzetti"), Marina Elena Cazzaniga(Azienda Ospedaliera San Gerardo), Alessandra Beano(Presidio Ospedaliero), Alberto Zaniboni(Fondazione Poliambulanza Istituto Ospedaliero), Raffaella Palumbo(Fondazione Salvatore Maugeri), Laura Biganzoli(Hospital of Prato), Mario Giuliano(Regione Campania), Agnese Latorre(Istituto Tumori Bari), Dario Bruzzese(University of Naples Federico II), Stefania Russo(National Center for Oncological Hadrontherapy), Mauro Truini(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Domenico Bilancia(Ospedale San Carlo), Andrea Michelotti(University of Pisa), Ferdinando Riccardi(Fatebenefratelli Hospital), Maria Malagoli, Francesco Schettini(Target (United States))
Cited by 15
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k